Blueprint Medicines Corporation or Lantheus Holdings, Inc.: Who Invests More in Innovation?

Blueprint vs. Lantheus: R&D Investment Showdown

__timestampBlueprint Medicines CorporationLantheus Holdings, Inc.
Wednesday, January 1, 20143184400013673000
Thursday, January 1, 20154858800014358000
Friday, January 1, 20168113100012203000
Sunday, January 1, 201714468700018125000
Monday, January 1, 201824362100017071000
Tuesday, January 1, 201933145000020018000
Wednesday, January 1, 202032686000032788000
Friday, January 1, 202160103300044966000
Saturday, January 1, 2022477419000311681000
Sunday, January 1, 202342772000077707000
Monday, January 1, 2024341433000
Loading chart...

Unveiling the hidden dimensions of data

Investing in Innovation: A Tale of Two Companies

In the competitive landscape of biotechnology and pharmaceuticals, innovation is the key to success. Blueprint Medicines Corporation and Lantheus Holdings, Inc. have been at the forefront of this race, each with a unique approach to research and development (R&D) investments. Over the past decade, Blueprint Medicines has consistently outpaced Lantheus Holdings in R&D spending, with an average annual investment nearly five times greater. In 2021, Blueprint Medicines reached its peak, allocating approximately 60% more to R&D than in previous years. Meanwhile, Lantheus Holdings has shown a steady increase, with a notable spike in 2022, where their R&D expenses surged by over 600% compared to 2014. This data highlights the strategic priorities of these companies and underscores the importance of R&D in driving innovation and growth in the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025